Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations
- 1 June 2026
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 46 (3) , e517508
Abstract
While immune checkpoint inhibitors have transformed treatment for many cancers, their benefit remains limited across all tumor types and is constrained by immune-related toxicity. Targeted immunotherapies, including T-cell engagers (TCEs), offer a more selective strategy by directing immune activity toward tumor-associated antigens. TCEs have achieved major success in hematologic malignancies and now show promise in selected solid tumors, with the approvals of tebentafusp and tarlatamab in uveal melanoma and small cell lung cancer, respectively, establishing proof of concept that durable benefit is possible. However, TCE efficacy is balanced by class-specific toxicities such as cytokine release syndrome and neurotoxicity, as well as on-target off-tumor effects. Antibody-drug conjugates (ADCs) can also enhance the specificity of cancer treatment by directing cytotoxic activity toward tumor cells via specific targets. ADC-checkpoint inhibitor combinations are similarly reshaping solid tumor therapy, most notably in urothelial carcinoma, where enfortumab vedotin plus pembrolizumab has demonstrated substantial survival gains. Across both strategies, efficacy may be influenced by antigen density, tumor heterogeneity, microenvironmental suppression, and treatment sequencing. Emerging drug engineering approaches and biomarker-driven patient selection aim to improve efficacy while limiting toxicity. Together, these advances support a new era of precision immuno-oncology, but broader success will require improved biomarkers, rational combinations, and an understanding of resistance mechanisms.Keywords
This publication has 168 references indexed in Scilit:
- HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based CombinationsTargeted Oncology, 2025
- Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trialAnnals of Oncology, 2025
- 61O Updated results of a phase II trial evaluating an anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascitesAnnals of Oncology, 2024
- 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamigAnnals of Oncology, 2024
- Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsCancer Immunology, Immunotherapy, 2024
- PSMA: a game changer in the diagnosis and treatment of advanced prostate cancerMedical Oncology, 2021
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint BlockadeJAMA Oncology, 2019
- The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityCancer Immunology, Immunotherapy, 2017
- Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunityInternational Journal of Cancer, 2013
- Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapyCancer Immunology, Immunotherapy, 1997